The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

Slate Medicines, a biotech company developing migraine treatments, announced the appointment of Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of life sciences leadership experience, including serving as CFO at Verona Pharma during its $10 billion acquisition by Merck in 2025. His appointment comes as Slate advances SLTE-1009, a PACAP-targeting therapeutic for migraine prevention.

The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities include oral GLP-1 agonists, next-generation incretin drugs, and convenient non-injectable options for obesity management.

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

Cosmos Health has partnered with Libytec Pharmaceutical to commercialize DIABIT-IS X (sitagliptin), a generic diabetes medication, in Greece. Under a five-year agreement, Cosmos will supply the drug while Libytec handles distribution and promotion. As a prescription medicine covered by Greece's national health insurance system, DIABIT-IS X is positioned to reach a broad patient population and contribute meaningfully to revenue and cash flow.

Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

The iShares Core High Dividend ETF (HDV) has gained over 15% year-to-date, outperforming the S&P 500's 9% return. The fund's success is driven by its high-quality dividend stock selection and significant exposure to energy stocks (ExxonMobil, Chevron) and healthcare stocks (AbbVie, Merck), which have all posted strong gains. HDV's focus on financially healthy companies with sustainable competitive advantages has delivered consistent returns over multiple time periods.

Moderna's stock has more than doubled this year as the company transitions from a COVID-19 vaccine maker to a diversified biotech firm. With multiple late-stage vaccine programs (flu, norovirus, combination vaccines) and cancer therapies in development, the company is preparing for major product launches in 2027-2028. Strong financials including $7.5 billion in cash and improving revenue support long-term growth potential, though recent gains reflect high expectations and clinical risks remain.

The article examines three dividend-focused ETFs as wealth-building alternatives to growth stocks. SCHD offers higher yields through value-oriented dividend stocks, VIG combines growth potential with rising dividends, and DGRO provides a balanced hybrid approach. All three can build serious long-term wealth through dividend reinvestment if held patiently.

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a long-term holding for passive income, offering a 3.25% dividend yield—more than three times the S&P 500's 1.07%. The ETF tracks 100 dividend-paying companies with at least 10 years of consecutive dividend payments and has seen its payout rise 211% over the past decade. Year-to-date performance shows 18.9% total return versus the S&P 500's 8.1%.